Although HER2-targeted therapies have shown limited efficacy in unselected ovarian cancer populations, our findings suggest that biomarker-guided strategies that include combination therapy may enhance therapeutic outcomes in resistant cases 55, 56. Here, ERBB2 is linked to ovarian carcinoma.